Anzeige
+++40 Mio. USD Staatsaufträge bis 2029, doch die Aktie notiert noch bei 0,67 CAD+++
Portfolio Tracker
Dein Depot in Echtzeit – Kurse, Renditeanalyse und Dividendenplaner an einem Ort.
Anzeige
EQS-News

Sino Biological Advances AI-Designed Molecule Validation With 4RISE(TM) 09.11.2026, 16:27 Uhr von EQS News Jetzt kommentieren: 0

EQS-News: Sino Biological / Key word(s): Manufacturing
Sino Biological Advances AI-Designed Molecule Validation With 4RISE(TM)

09.11.2026 / 16:27 CET/CEST
The issuer is solely responsible for the content of this announcement.


Faster Expression. Deeper Validation. Integrated Support.

HOUSTON, TEXAS - November 9, 2026 (NEWMEDIAWIRE) - AI can generate protein candidates at an unprecedented speed, but experimental validation remains essential to determine whether they properly express, bind targets, and demonstrate the desired biological properties.

Sino Biological, Inc. (Shenzhen Stock Exchange: 301047.SZ), a global leader in recombinant protein technology, brings these capabilities together under 4RISETM, an integrated wet-lab validation solution designed to advance AI-designed molecules from computational predictions to experimental evidence.

Built around four strengths - Rapid, In-Depth, Seamless, and Empirical - 4RISETM brings together high-throughput expression, extensive target protein resources, and multi-dimensional validation capabilities.

4RISETM: Turning AI Designs into Experimental Evidence

R - RAPID Rapid Expression. Ready-to-Use Targets. Faster Readout.

XPressMAX™ cell-free protein synthesis (CFPS) enables recombinant protein expression in approximately 3 hours, with success rates exceeding 99% in established workflows. Combined with more than 11,000 ready-to-use target proteins and high-throughput SPR/BLI analysis, applicable workflows can also deliver AI-ready binding data in as little as 3 days. Structured, AI-ready experimental data and API access support data retrieval and integration into downstream research, analysis, and optimization workflows. By accelerating expression, screening, and data delivery, 4RISETM helps researchers rapidly identify promising candidates and advance AI-driven design cycles.

I - IN-DEPTH Beyond Binding. Into Biology.

4RISETM goes beyond target binding and kinetic characterization to assess developability and biological function. More than 20 developability assays, alongside molecular and cell-based functional assays, help researchers evaluate candidate quality and biological activity.

S - SEAMLESS Versatile Expression. Extensive Target Coverage. Integrated Validation.

Complementary cell-free and mammalian expression platforms support diverse molecule types and expression requirements. Combined with an extensive in-house target protein portfolio, antibody production, binding characterization, developability assessment, and functional validation, 4RISETM provides integrated support from sequence screening to candidate evaluation.

E - EMPIRICAL Proven in Practice.

Sino Biological brings established high-throughput expression, purification, and analytical platforms, with experience supporting diverse AI-designed molecules, including miniproteins, VHH, scFv, Fab, IgG, enzymes, and cytokines. With collaborations spanning more than 50 AI companies, Sino Biological brings extensive hands-on experience in wet-lab validation of AI-designed molecules.

Advancing AI Discovery with Experimental Evidence

"AI-driven discovery requires more than computational predictions. Researchers need reliable experimental evidence to evaluate candidates and guide subsequent design decisions," said Dr. Rob Burgess, Chief Business Officer at Sino Biological US. "4RISE™ combines rapid expression, extensive target resources, and in-depth validation to help researchers move faster and gain deeper insights."

As AI continues to expand the possibilities of recombinant protein design, Sino Biological remains committed to advancing the experimental capabilities that bring these innovations closer to reality.

Learn more about 4RISE™ High-Throughput Wet-Lab Validation Services: https://www.sinobiological.com/services/htp-platform-for-ai-driven-antibody-discovery

About Sino Biological

Sino Biological is a global biotechnology company specializing in high-quality recombinant proteins, antibodies, and customized research services. Serving researchers in more than 90 countries, Sino Biological supports basic research, drug discovery, vaccine development, and diagnostics through its comprehensive product portfolio, proprietary quality systems, and innovative research platforms.

Forward-Looking Statements

Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on Sino Biological management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, over which Sino Biological has no control. Sino Biological assumes no obligation to update these forward-looking statements and does not intend to do so.

For media inquiries or partnership opportunities, please contact:

Sino Biological, Inc.
gmo@sinobiological.cn
www.sinobiological.com

View the original release on www.newmediawire.com


News Source: Sino Biological


09.11.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


Language: English
Company: Sino Biological
United States
ISIN: CNE100004Q23
EQS News ID: 2431116

 
End of News EQS News Service

2431116  09.11.2026 CET/CEST

Kommentare (0) ... diskutiere mit.
Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer